Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Exploring the endocannabinoid system within autosomal recessive spastic ataxia of the Charlevoix-Saguenay

FY 2023-24

Summary
Background: Autosomal recessive spastic ataxia of the Charlevoix-Saguenay (ARSACS) is a neurological disorder linked to sacsin protein dysfunction, leading to symptoms of poor muscle coordination (ataxia), peripheral nerve dysfunction (polyneuropathy), and muscle stiffening. To date, sacsin’s functions remain uncharacterized; however, our research has revealed that sacsin interacts with an enzyme in the endocannabinoid system, ?/?-hydrolase domain 12 (ABHD12). The endocannabinoid system shapes neurodevelopmental processes, with ABHD12 as a key player in modulating neurotransmission. ABHD12 is linked to a neurological disorder that shares symptoms with ARSACS, known as PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataracts). Similarities between PHARC and ABHD12 suggest a common pathological mechanism, prompting us to investigate the endocannabinoid system within ARSACS pathology. Objective: To characterize the role of sacsin on ABHD12-mediated endocannabinoid signalling, hypothesizing that the endocannabinoid system is involved in ARSACS development. Methods: Using the ARSACS mouse model, we will compare Sacs knockout mice with wild-type controls, generating primary cell cultures of Purkinje neurons and microglia. Cortical, spinal cord, and cerebellar tissues are already available. In our models, we will assess ABHD12 and cannabinoid receptor expression and localization with Western Blot and Immunohistochemistry analyses. We will measure lipid and cytokine profiles using lipidomics and immunoassays. Finally, we will transition to in vivo mouse models to validate our findings. Significance: The proposed study constitutes an unexplored avenue of ARSACS etiology that has the potential to forge new treatment strategies for ARSACS patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
505859
Name
Atkinson Caitlin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the endocannabinoid system within autosomal recessive spastic ataxia of the Charlevoix-Saguenay
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Abhd12; Arsacs; Ataxia; Cellular Biology; Endocannabinoid; Genetic Diseases; Neurological Disease; Sacsin
Abstract
Background: Autosomal recessive spastic ataxia of the Charlevoix-Saguenay (ARSACS) is a neurological disorder linked to sacsin protein dysfunction, leading to symptoms of poor muscle coordination (ataxia), peripheral nerve dysfunction (polyneuropathy), and muscle stiffening. To date, sacsin’s functions remain uncharacterized; however, our research has revealed that sacsin interacts with an enzyme in the endocannabinoid system, ?/?-hydrolase domain 12 (ABHD12). The endocannabinoid system shapes neurodevelopmental processes, with ABHD12 as a key player in modulating neurotransmission. ABHD12 is linked to a neurological disorder that shares symptoms with ARSACS, known as PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataracts). Similarities between PHARC and ABHD12 suggest a common pathological mechanism, prompting us to investigate the endocannabinoid system within ARSACS pathology. Objective: To characterize the role of sacsin on ABHD12-mediated endocannabinoid signalling, hypothesizing that the endocannabinoid system is involved in ARSACS development. Methods: Using the ARSACS mouse model, we will compare Sacs knockout mice with wild-type controls, generating primary cell cultures of Purkinje neurons and microglia. Cortical, spinal cord, and cerebellar tissues are already available. In our models, we will assess ABHD12 and cannabinoid receptor expression and localization with Western Blot and Immunohistochemistry analyses. We will measure lipid and cytokine profiles using lipidomics and immunoassays. Finally, we will transition to in vivo mouse models to validate our findings. Significance: The proposed study constitutes an unexplored avenue of ARSACS etiology that has the potential to forge new treatment strategies for ARSACS patients.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Atkinson, Caitlin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~